Author: Ravi Shankar

Series D Preferred Stock to be offered at $10.00 per share through the issuance of tokens and issued natively on-chain, with T7X Equities serving as transfer agent; no common stock will be issued at closing

DALLAS, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced a partnership with T7X, a compliance-first digital asset infrastructure company, to issue a new series of tokenized preferred stock natively on T7X’s blockchain infrastructure. Upon issuance, Mangoceuticals expects to become the first Nasdaq-listed company to issue a security on the T7X platform. In connection with the offering, the Company today filed an offering statement on Form 1-A with the SEC.

The Company intends to offer up to 1,000,000 shares of its Series D Cumulative Convertible Preferred Stock (the “Preferred Stock”) at $10.00 per share, for gross proceeds of up to $10 million, subject to SEC qualification of the Company’s offering statement. The offering will be a Tier 2 offering under Regulation A of the Securities Act of 1933, as amended. The Preferred Stock will carry cumulative dividends at an annual rate of 8% of the original $10.00 stated value, accruing on a simple, non-compounding basis and payable quarterly in cash when, as and if declared by the Company’s Board of Directors. T7X Equities, Inc., an SEC-registered transfer agent, will maintain the official securityholder records. The Company intends to use the net proceeds for general corporate purposes and working capital.

No shares of Mangoceuticals common stock will be issued at the closing of the offering. Beginning three years from the date of issuance, the Preferred Stock will be convertible into shares of the Company’s common stock at a fixed conversion price equal to 300% of the volume-weighted average closing price of the Company’s common stock on Nasdaq on for the ten trading days immediately preceding SEC qualification of the offering statement, but may not be less than the floor price described in the offering statement. The conversion terms are designed to defer any potential issuance of common stock and to tie it to a significantly higher share price, limiting near-term dilution to the Company’s common shareholders. In addition, the transfer restrictions built into the T7X platform are designed to restrict the use of the Preferred Stock for short selling or hedging against the Company’s common stock.

The Preferred Stock will be issued natively on-chain on the Trusted Smart Chain, the blockchain that underpins T7X’s tokenization infrastructure. Each token will represent a direct ownership interest in the Preferred Stock as recorded by T7X Equities in the master securityholder file, rather than a digital representation of shares held through a traditional intermediary. Compliance controls are built directly into the protocol layer of T7X’s blockchain, rather than managed through third-party middleware. These controls include identity verification (KYC), anti-money laundering (AML) screening and programmable transfer restrictions, so tokens can move only between wallets linked to verified investors. Because ownership records are maintained on-chain, transfers are designed to be recorded in the securityholder file at the time they occur, with compliance checks applied to each transfer.

“We believe tokenized securities represent the next evolution of the capital markets, and upon issuance we expect to be the first Nasdaq-listed company to bring a security to T7X’s platform,” said Jacob D. Cohen, Chief Executive Officer of Mangoceuticals. “This structure gives investors access to a dividend-paying security with the transparency and settlement efficiency of the blockchain, while allowing us to raise capital without issuing common stock today, and with conversion fixed at a substantial premium to our share price. It continues our focus on financing structures that limit dilution to our common shareholders as we pursue opportunities to create long-term shareholder value.”

“We are thrilled to have Mangoceuticals issuing its securities on our tokenized blockchain infrastructure,” said Pablo Penaloza, Chief Executive Officer of T7X. “Mangoceuticals is taking a meaningful step in bringing a public company onto native on-chain infrastructure. By embedding identity verification, anti-money laundering controls and transfer restrictions directly into the issuance, we believe this offering demonstrates how listed companies can access tokenized capital formation within existing securities laws.”

Today, the Company filed an offering statement on Form 1-A with the U.S. Securities and Exchange Commission (the “SEC”) relating to the Preferred Stock. The offering statement has not yet been qualified by the SEC, and the information it contains is subject to completion or amendment. The preliminary offering circular is available on the SEC’s website here, or by contacting the Company at 17130 N. Dallas Parkway, Suite 240, Dallas, Texas 75248, or by email at investors@mangorx.com.

No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance is given after the qualification date. An indication of interest involves no obligation or commitment of any kind.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Mangoceuticals, Inc.
MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

About T7X
T7X is a compliance-first digital asset infrastructure company focused on regulated tokenization and modern capital formation. T7X operates as a registered transfer agent through T7X Equities, issuing digital securities natively on-chain with compliance enforcement at the protocol level. For more information, visit www.t7x.io.

Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target,” “up to” or similar words or phrases. These forward-looking statements include, but are not limited to, statements regarding the qualification of the Company’s offering statement on Form 1-A by the SEC; the expected terms, timing, size and completion of the Preferred Stock offering; the issuance of the Preferred Stock in tokenized form on T7X’s blockchain infrastructure; the expected functionality of T7X’s compliance, recordkeeping and transfer infrastructure, including its omnibus-wallet structure and transfer restrictions; any future transferability or trading of the Preferred Stock or corresponding token and the development of any trading market therefor; the declaration and payment of dividends on the Preferred Stock; the conversion of the Preferred Stock into common stock, the determination of the conversion price and any resulting dilution; the Company’s expectation that it will be the first Nasdaq-listed company to issue a security with a corresponding tokenized administrative record through T7X; the anticipated use of proceeds; and the anticipated benefits of tokenized administrative records to the Company and investors. The declaration and payment of dividends is at the discretion of the Board of Directors and subject to applicable law and the Company’s financial condition. Conversion of the Preferred Stock into common stock, if it occurs, would result in dilution to the Company’s common shareholders. Tokenized securities and blockchain-based records are subject to evolving regulation and to technological, cybersecurity and operational risks. The Preferred Stock will not be listed on any exchange or alternative trading system at issuance, the corresponding token is currently non-tradeable, investors cannot presently initiate token transfers, and tokens cannot be transferred outside the T7X omnibus wallet. There can be no assurance that the Preferred Stock or corresponding token will become eligible for trading or that an active trading market will develop. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and other subsequent reports. These filings are available at https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=MGRX and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contacts
Investor Relations: investors@mangorx.com
T7X Media: Ivan Kan, CMO | ivan@t7x.io | www.t7x.io

Subsidiary YY Circle Singapore Selected to Supply On-Demand Frontline Workforce Across Major Quick-Service Restaurant Network

SINGAPORE, Nov. 12, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (NASDAQ: YFOR) (“YYForce” or the “Company”), an AI-enabled frontline workforce, robotics, and facility solutions provider, today announced that its subsidiary, YY Circle Singapore, has entered into an agreement to supply part-time frontline staff across a major quick-service restaurant (QSR) operator’s nationwide network of more than 100 outlets in Singapore.

Key Highlights:

• Nationwide QSR Footprint: Establishes an island-wide staffing framework covering more than 100 quick-service restaurant locations across Singapore.
• AI-Enabled On-Demand Deployment: Leverages YY Circle’s digital workforce matching platform to manage sourcing, onboarding, and shift allocation during peak trading windows.
• Scalable Food-Service Expansion: Expands YYForce’s commercial footprint across Singapore’s high-volume food and beverage sector while creating flexible work opportunities island-wide.

Under the terms of the agreement, YY Circle Singapore will serve as a nationwide workforce partner supporting outlet-level staffing requirements across the customer’s entire Singapore network. Deployments are structured on an on-demand basis to address peak trading periods, dynamic shift coverage, and fluctuating operational requirements across individual locations.

Through its digital platform, YY Circle Singapore will manage end-to-end worker sourcing, onboarding, and deployment. The engagement demonstrates the scalability of YYForce’s technology-enabled staffing model across multi-site retail and food-service enterprises.

“Securing a nationwide staffing agreement spanning more than 100 outlets is an important commercial milestone for YY Circle Singapore,” said Mike Fu, Chief Executive Officer and Chairman of YYForce. “Our focus is on translating island-wide network coverage into dependable, high-standard execution at every individual location. By pairing our digital workforce coordination capabilities with a deep pool of verified frontline talent, we are helping major food-service operators scale efficiently while creating flexible work opportunities across Singapore.”

The agreement reinforces YYForce’s broader strategy of uniting human talent, AI-enabled workforce coordination, and commercial robotics to optimize frontline operations across high-frequency service industries.

The identity of the customer and specific commercial terms remain confidential. Coverage across the customer’s network does not represent simultaneous staffing deployments at every outlet or a guaranteed minimum volume of assignments.

About YYForce Inc.

YYForce Inc. (NASDAQ: YFOR) is an AI-enabled workforce solutions and integrated facility management provider operating across Asia and beyond. Driven by its mission to transform frontline work through AI, robotics, and integrated workforce solutions, the Company brings together people, intelligent software, and commercial robotics into one connected ecosystem. Its portfolio spans intelligent workforce matching (YY Circle, Yolara AI), digital estate management (24iFM), and service robot deployment, leasing, maintenance, and humanoid robotics development—serving hospitality, facilities management, retail, logistics, and other frontline-driven industries. Guided by its vision to build the future of work where people and intelligent technology thrive together, YYForce helps businesses improve productivity, enhance everyday experiences, and build a smarter, more sustainable workforce. For more information, visit https://www.yyforce.ai.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning anticipated staffing deployments, business opportunities, customer relationships, and YYForce’s strategic objectives. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including customer staffing demand, worker availability, execution of the agreement, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. Nationwide coverage under the agreement does not guarantee deployment volumes or revenue. The Company undertakes no obligation to update forward-looking statements except as required by law.

Investor Relations & Corporate Inquiries

YYForce Inc. — Investor Relations Department
Email: ir@yyforce.ai
Website: https://www.yyforce.ai

Tivoxavir Marboxil Tablet Bridging Study Completed in Preparation for Additional Studies

• Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID^®, with no viral rebound through Day 28 and fewer treatment-related adverse events in subjects eligible to receive PAXLOVID^®
• Similar results were obtained in PAXLOVID^®-ineligible subjects, a population with limited oral treatment options, with no treatment-related adverse events
• Traws intends to discuss with the FDA a registration path focused on PAXLOVID^®-ineligible patients
• Tivoxavir marboxil (TXM)’s bridging study of a compressed tablet formulation achieved its objectives, supporting the potential for TXM’s once-monthly dosing regimen and use in further efficacy studies. TXM is an investigational long-acting prophylactic agent for seasonal and pandemic influenza
• TXM toxicology retesting completed, with two independent rat Pig-a gene mutation studies showing no mutagenic effect at doses up to 500 mg/kg and an improved margin compared with the original assay; regulatory resubmission planned for the fourth quarter of 2026

NEWTOWN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the final results of its 92-patient Phase 2a study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in subjects with mild-to-moderate COVID-19, and the completion of a bridging study of a compressed tablet formulation of tivoxavir marboxil (TXM), its investigational once-monthly antiviral for seasonal and pandemic influenza prophylaxis.

Ratutrelvir Phase 2a Results

The randomized, active-controlled study compared ratutrelvir 600 mg once daily for 10 days with PAXLOVID^® (nirmatrelvir/ritonavir) for 5 days in 62 subjects eligible for PAXLOVID^®, and evaluated ratutrelvir in a separate cohort of 30 subjects ineligible for PAXLOVID^®, most commonly because of contraindicated concomitant medications. Endpoints included time to sustained symptom resolution, nasal viral RNA, viral rebound and safety through Day 28.

In PAXLOVID^®-eligible patients, the median time to sustained symptom resolution was 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID^®. Viral RNA declined at a similar rate in both arms, and no virologic rebound was observed through Day 28. Treatment-related adverse events were reported in 1 of 32 ratutrelvir patients and 4 of 30 PAXLOVID^® patients. In PAXLOVID^®-ineligible subjects, who were older and had a high burden of cardiovascular and pulmonary comorbidities, ratutrelvir cleared virus at a rate similar to the randomized arms, symptoms resolved in 14.0 days, and no treatment-related adverse events were reported.

“These final results support the potential of ratutrelvir as a once-daily, ritonavir-free treatment option, including for patients who cannot take ritonavir-boosted therapy because of their other medications,” commented Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma. “The tolerability profile and the absence of viral rebound encourage further clinical evaluation.”

“Ratutrelvir’s potency across 12 SARS-CoV-2 strains, its activity against the resistance mutations that emerge with nirmatrelvir and ensitrelvir, and its preferential lung distribution were design objectives,” said C. David Pauza, PhD, Chief Science Officer of Traws Pharma. “We believe our clinical data is consistent with those properties and support a differentiated profile in COVID-infected subjects.”

Traws intends to discuss with the FDA a registration strategy focused on adults at high risk of progression to severe COVID-19 and ineligible for PAXLOVID^®. Discussions will include a potential adaptive Phase 2b/pivotal program and Fast Track designation.

Tivoxavir Marboxil (TXM) Tablet Bridging Study and Retest of Toxicology Package

Traws completed a healthy volunteer bridging study of the compressed tablet formulation of TXM conducted under an open investigational new drug (IND) application in Australia. The study showed that the tablet provides comparable exposure as powder-in-capsule and was well tolerated. Consistent with the Company’s earlier modeling, the tablet could support once-monthly dosing. The Company believes the results also support TXM’s use in further efficacy studies, including a planned human influenza challenge study.

Traws completed a retest of the toxicology package for TXM, including two independent studies in rats using the Pig-a gene mutation assay, a sensitive laboratory test that checks whether a drug causes genetic changes (mutations) in the blood-forming cells of the bone marrow. In both studies, no mutations were observed at doses up to 500 mg/kg. Effects were observed at 2,000 mg/kg and inconsistently at 1,000 mg/kg. Based on these results, the Company identified 500 mg/kg as the highest dose with no observed mutagenic effect in this model, representing a margin of approximately 125-fold over the planned clinical exposure based on dose. With the toxicology retest complete, the Company expects to resubmit the updated package to regulators in the fourth quarter of 2026.

“The recent human H5N1 cases in Washington State, linked to infected dairy cattle, come as seasonal influenza is already circulating on the West Coast. While health officials continue to assess the risk to the general public as low, having avian and seasonal influenza viruses active at the same time underscores the importance of being prepared. TXM has shown encouraging activity against H5N1 in preclinical studies, and we are working to advance it as a potential single-dose oral prevention option,” commented Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma.

Traws Outlook

“Ratutrelvir’s final data support its potential as a once-daily, ritonavir-free option for the treatment of COVID-19 infections for patients who are ineligible for PAXLOVID^®. As new SARS-CoV-2 variants such as PJ.2.1 emerge, changes in the spike protein can reduce the activity of antibody-based products. Ratutrelvir acts through a different mechanism. It inhibits the viral main protease, Mpro, an enzyme that is highly conserved across variants. Ratutrelvir has shown in vitro activity against all 12 SARS-CoV-2 strains tested to date, and we are evaluating its activity against PJ.2.1 and other emerging variants. In influenza, we believe the completion of the tablet bridging study is an important step toward a potential once-monthly prevention option for tivoxavir marboxil. We believe ratutrelvir and tivoxavir marboxil have the potential to address important unmet treatment and prevention needs. Our focus is on advancing both programs,” commented Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma.

About Ratutrelvir

Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to act broadly against SARS-CoV-2/COVID-19 strains without the need for ritonavir. It has demonstrated in vitro activity against a range of virus strains. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity.¹ Ratutrelvir has not been approved by any regulatory authority.

About Tivoxavir Marboxil

Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed for single dose treatment and prevention of seasonal influenza and bird flu. It has shown in vitro activity against a range of influenza strains in preclinical studies. Seasonal influenza represents an estimated multi-billion-dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders and inclusion in drug stock piling initiatives,^2,3 with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. TXM has not been approved by any regulatory authority.

Source information

1. Pfizer Inc. annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on February 3, 2026
2. Per link
3. Traws data on file

Third-party products mentioned herein are the trademarks of their respective owners. PAXLOVID® is a registered trademark of Pfizer Inc.

About Traws Pharma, Inc.

Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to address real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral designed to have potent activity against difficult-to-treat or resistant virus strains. These include viruses associated with seasonal influenza and H5N1 bird flu, as well as negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, and Lassa Fever and viruses associated with COVID-19/Long COVID.

PAXLOVID® is a registered trademark of Pfizer Inc.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for ratutrelvir and tivoxavir marboxil, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “potential”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including planned discussions with the FDA, potential Fast Track designation, the outcome of Traws’ IND filing with the U.S. Food and Drug Administration (FDA) for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; the potential for tivoxavir marboxil or ratutrelvir to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, Biomedical Advanced Research and Development Authority (BARDA) and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval; the extent of the spread and threat of the bird flu; COVID-19; seasonal flu; the Company’s cash projections; Traws’ ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.

Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com

Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the 2026 Jefferies Global Healthcare Conference in London, United Kingdom taking place from November 16–19, 2026.

The Leadership team will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Jefferies representative.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

Investor inquiries or meeting requests:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: ir@okyopharma.com

First quarter revenue rises 9.3% to $16.4 million; GAAP net income of $0.16 million compared with a net loss in the prior-year period

ENCINO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, reported results for its fiscal first quarter ended September 30, 2026. 

First quarter highlights 

• First quarter revenue increased 9.3% to $16.4 million, compared with $15.0 million in the prior-year period; subscription and support revenue increased 6.1% to $9.5 million. 
• First quarter gross margin expanded by more than 1,100 basis points to 50.5%, compared with 39.4% in the prior-year period; income from operations was $0.4 million, compared with an operating loss of $1.8 million. 
• First quarter GAAP net income attributable to NETSOL was $0.16 million, or $0.01 per diluted share, compared with a net loss of $2.36 million, or $0.21 per diluted share, in the prior-year period. 
• First quarter adjusted EBITDA attributable to NETSOL was $0.48 million, compared with negative $1.66 million in the prior-year period. 
• Net cash used in operating activities was $5.6 million, primarily attributable to working capital; cash and cash equivalents were $19.7 million at September 30, 2026.

First quarter fiscal 2027 financial results 

Revenue 

Total net revenues for the first quarter of fiscal 2027 increased 9.3% to $16.4 million, compared with $15.0 million in the prior-year period. On a constant currency basis, total net revenues were $16.5 million. First quarter revenue and gross margin were each the highest for a first quarter in the past five fiscal years. 

Subscription (SaaS and Cloud) and support revenues increased 6.1% to $9.5 million, compared with $9.0 million in the prior-year period. 

Services revenues increased 6.3% to $6.4 million, compared with $6.0 million in the prior-year period. 

Gross profit and operating income 

Gross profit increased to $8.3 million, or 50.5% of net revenues, compared with $5.9 million, or 39.4% of net revenues, in the prior-year period. Gross margin expanded by more than 1,100 basis points. 

Gross margin benefited from revenue mix and the capitalization of approximately $1.0 million of software development costs, compared with none in the prior-year period. 

Headcount was 1,272 at September 30, 2026, compared with 1,370 at June 30, 2026 and 1,442 at September 30, 2025. 

Income from operations was $0.4 million, compared with a loss from operations of $1.8 million in the prior-year period, representing an operating margin of 2.5% compared with negative 12.2%. 

Net income and non-GAAP results 

GAAP net income attributable to NETSOL was $0.16 million, or $0.01 per diluted share, compared with a net loss of $2.36 million, or $0.21 per diluted share, in the prior-year period. 

Consolidated net income was $0.53 million, compared with a consolidated net loss of $2.22 million in the prior-year period. Net income attributable to non-controlling interests was $0.37 million, compared with $0.14 million. 
The improvement reflects stronger gross margin performance and a significantly narrower foreign currency exchange loss of $7,000, compared with $287,000 in the prior-year period. 

Non-GAAP results for the first quarter, compared with the prior-year period, were: 

• Non-GAAP EBITDA: $0.78 million, compared with negative $1.78 million. 
• Consolidated adjusted EBITDA: $0.89 million, compared with negative $1.35 million. 
• Adjusted EBITDA attributable to NETSOL: $0.48 million, compared with negative $1.66 million. 

Cash flow and balance sheet 

Net cash used in operating activities for the first quarter was $5.6 million, compared with $5.3 million provided by operating activities in the prior-year period. The change was primarily attributable to working capital: contract liabilities decreased $3.4 million, contract assets increased $2.6 million and accounts payable and accrued expenses decreased $1.5 million, partially offset by a $1.1 million decrease in accounts receivable. The company also invested approximately $2.0 million in property, equipment and capitalized software development, compared with approximately $0.5 million in the prior-year period. This included approximately $1.0 million of capitalized software development costs, compared with none in the prior-year period, which also contributed to the gross margin improvement.

Cash and cash equivalents were $19.7 million at September 30, 2026 compared with $27.1 million at June 30, 2026, reflecting the working capital movements described above. Working capital was $29.1 million at September 30, 2026.  

NETSOL stockholders’ equity was $42.0 million at September 30, 2026. 

On October 30, 2026, the board of NETSOL Technologies Limited, the company’s majority-owned subsidiary listed on the Pakistan Stock Exchange, recommended a buy-back of up to 4,000,000 of its shares, approximately 4.45% of its issued capital, to be held in treasury and funded from the subsidiary’s distributable profits. The proposal is subject to shareholder approval on December 3, 2026. The company is not assigning a financial benefit to the proposal at this stage. 

Separately, on October 1, 2026, the Board of NETSOL Technologies Europe Limited began evaluating strategic alternatives for its subsidiary Virtual Lease Services Limited (VLS), including a potential sale or wind-down, though no plan has been approved or agreement executed. VLS revenue for the three months ended September 30, 2026 represented approximately 1.7% of consolidated revenues, and its total assets represented approximately 1.3% of total consolidated assets. If a sale or wind-down is completed, the company may recognize a loss on disposal and incur exit-related costs, which cannot be estimated at this time.

Management commentary 

Najeeb Ghauri, Founder and Chief Executive Officer of NETSOL Technologies, Inc., commented: 

“This quarter shows the kind of progress we set out to deliver entering fiscal 2027. Revenue, gross margin and profitability all moved in the right direction compared with a year ago, and we did it while continuing to strengthen our commercial pipeline and deepen trust with our largest customers. That combination, growth, margin improvement and deepening customer relationships, is what we mean when we talk about making this company’s performance more predictable.” 

Asad Ghauri, Global Head of Sales and Group Managing Director of Europe at NETSOL Technologies, Inc., commented: 

“We saw strong commercial momentum this quarter. We brought Transcend Retail live across two new U.S. dealerships, Atlanta Autos and Royal Coach RV, and BMO Equipment Finance, a 30-year customer, moved from our legacy LeasePak platform onto Transcend Finance, part of a broader pattern we’re seeing across our install base.” 

Sardar Abubakr, Chief Financial Officer of NETSOL Technologies, Inc., commented: 

“The first quarter marked a clear improvement from where we stood a year ago. Revenue grew 9.3%, gross margin expanded more than 1,100 basis points and we moved from an operating loss to operating income, with net income attributable to NETSOL of $0.16 million compared with a loss of $2.36 million a year ago.” 

“In the fourth quarter we billed and collected ahead of delivery, and in the first quarter we delivered against those billings. That is most of the operating cash outflow. Our liquidity is fine and we can fund the business through the year.” 

“Our priorities for the remainder of the year are unchanged: grow recurring revenue, build on this quarter’s year-over-year margin gains and continue converting consolidated performance into value for NETSOL shareholders.”  

Conference call 

NETSOL Technologies management will hold a conference call Thursday, November 12, 2026, at 9:00 am Eastern Time (6:00 am Pacific Time) to discuss its results for the first quarter of fiscal 2027 ended September 30, 2026. A question-and-answer session will follow management’s prepared remarks. 

Participant dial-in: 1-877-407-0789 or 1-201-689-8562  

A live webcast of the conference call will be available here. Information about the webcast will also be available on the Investor Relations section of NETSOL’s website at www.netsoltech.com. 

Telephone replay:

Telephone replays will be made available approximately 3 hours after conference end time. 

Replay dial-in: 1-844-512-2921 or 1-412-317-6671 

Replay expiration: Thursday, November 26, 2026 at 11:59 PM ET 

Access ID: 13763709  

About NETSOL Technologies  
NETSOL Technologies delivers state-of-the-art solutions for asset finance, leasing and digital automotive retail, serving automotive and equipment OEMs, dealerships, auto captives and financial institutions across over 30 countries. Since its inception in 1997, NETSOL has been at the cutting edge of technology, pioneering innovations with its asset finance solutions, and today leverages advanced AI and cloud services to meet the complex needs of the global market. Renowned for its deep industry expertise, customer-centric approach and commitment to excellence, NETSOL fosters strong partnerships with its customers, ensuring their success in an ever-evolving landscape. With a rich history of innovation, ethical business practices and a focus on sustainability, NETSOL is dedicated to empowering businesses worldwide, securing its position as the trusted partner for leading firms around the globe. 

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company’s products and services, expectations for future operations, fiscal 2027 guidance for revenues, gross margin and adjusted EBITDA, contracted revenue, remaining performance obligations and revenue visibility, AI-enabled products and productivity initiatives, the company’s efficiency program, capital allocation, potential strategic partnerships and acquisitions, potential structural actions concerning non-controlling interests, and other statements that are not historical facts. These forward-looking statements may be identified by terminology such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “targets,” “guidance,” “assumes,” and similar expressions. These statements are not guarantees of future performance and are subject to a number of risks, uncertainties, and assumptions that are difficult to predict. The fiscal 2027 outlook assumes continued subscription growth, execution of contracted implementations, disciplined cost management and no material acquisitions. Factors that could cause actual results to differ materially include, but are not limited to, the timing of customer agreements, go-lives, contract signings and renewals, implementation milestones, the rate of adoption of AI-enabled product capabilities, foreign currency volatility, customer concentration and customer decisions, the timing of advance billings and collections, investment levels, competition, geopolitical and macroeconomic conditions, and other factors discussed in NETSOL’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. NETSOL undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. 

Use of Non-GAAP financial measures 
This press release includes references to non-GAAP EBITDA, non-GAAP adjusted EBITDA, gross, and non-GAAP adjusted EBITDA, net, which are non-GAAP financial measures. Non-GAAP EBITDA is net income before non-controlling interest, income taxes, depreciation and amortization, interest expense and interest income. Non-GAAP adjusted EBITDA, gross, further excludes foreign currency exchange gains and losses and non-cash stock-based compensation; non-GAAP adjusted EBITDA, net, further deducts the adjusted EBITDA attributable to non-controlling interests. Management believes these measures assist investors in evaluating operating performance and comparing results across periods. Non-GAAP measures should be considered in addition to, and not as substitutes for, the most directly comparable GAAP measures. Reconciliations of these measures to net income attributable to NETSOL, the most directly comparable GAAP measure, together with an explanation of how management uses these measures, are provided in Schedule 4 of the financial tables that follow. 

Investor Relations Contact: 
Investor Relations 
(818) 222-9195 
investors@netsoltech.com 

NETSOL Technologies, Inc. and Subsidiaries
Schedule 1: Consolidated Balance Sheets
ASSETS			September 30, 2026				As of June 30, 2026
Current assets:
Cash and cash equivalents		$19,697,789				$27,123,955
Accounts receivable, net of allowance of $161,853 and $48,606			9,144,194				10,286,342
Contract assets, net of allowance of $0 and $10			18,977,455				16,240,564
Other current assets			4,160,460				3,210,315
Total current assets		$51,979,898				$56,861,176
Contract assets, net – long term			2,483,199				2,467,018
Property and equipment, net			5,550,633				5,683,502
Right of use assets – operating leases			795,642				831,196
Other assets			7,242				7,241
Other intangible assets, net			3,619,868				2,686,392
Goodwill			9,302,524				9,302,524
Total assets		$73,739,006				$77,839,049
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses		$7,276,077				$8,708,029
Current portion of loans and obligations under finance leases			8,139,155				8,187,170
Current portion of operating lease obligations			499,603				447,332
Contract liabilities			6,941,958				10,287,225
Total current liabilities		$22,856,793				$27,629,756
Loans and obligations under finance leases; less current maturities			174,082				212,982
Operating lease obligations; less current maturities			260,146				428,491
Total liabilities		$23,291,021				$28,271,229
Stockholders’ equity:
Preferred stock, $.01 par value; 500,000 shares authorized;			–				–
Common stock, $.01 par value; 18,000,000 shares authorized; 12,910,343 shares issued and 11,971,312 outstanding as of September 30, 2026, 12,825,028 shares issued and 11,885,997 outstanding as of June 30, 2026			129,106				128,253
Additional paid-in-capital			130,276,620				130,188,049
Treasury stock (at cost, 939,031 shares as of September 30, 2026 and June 30, 2026)			(3,920,856)				(3,920,856)
Accumulated deficit			(38,175,758)				(38,338,727)
Other comprehensive loss			(46,295,697)				(46,462,794)
Total NetSol stockholders’ equity		$42,013,415				$41,593,925
Non-controlling interest			8,434,570				7,973,895
Total stockholders’ equity		$50,447,985				$49,567,820
Total liabilities and stockholders’ equity		$73,739,006				$77,839,049

Schedule 2: Consolidated Statements of Operations
		For the Three Months Ended September 30,
		2026				2025
Net Revenues:
License fees			549,263				72,225
Subscription and support			9,505,208				8,960,555
Services			6,357,989				5,979,143
Total net revenues		$16,412,460				$15,011,923
Cost of revenues		$8,131,365				$9,099,933
Gross profit		$8,281,095				$5,911,990
Operating expenses:
Selling, general and administrative			7,700,709				7,536,353
Research and development cost			171,626				214,343
Total operating expenses		$7,872,335				$7,750,696
Income (loss) from operations		$408,760				($1,838,706)
Other income and (expenses)
Interest expense			(111,360)				(174,611)
Interest income			301,068				280,974
Gain (loss) on foreign currency exchange transactions			(6,811)				(286,917)
Other income			47,677				17,670
Total other income (expenses)		$230,574				($162,884)
Net income (loss) before income taxes		$639,334				($2,001,590)
Income tax provision			(105,126)				(215,775)
Net income (loss)		$534,208				($2,217,365)
Non-controlling interest			(371,239)				(139,923)
Net income (loss) attributable to NetSol		$162,969				($2,357,288)
Net income (loss) per share:
Net income (loss) per common share
Basic		$0.01				($0.21)
Diluted		$0.01				($0.21)
Weighted average number of shares outstanding
Basic			11,906,981				11,429,695
Diluted			11,926,869				11,429,695

Schedule 3: Consolidated Statements of Cash Flows
		For the Three Months Ended September 30,
		2026				2025
Cash flows from operating activities:
Net income (loss)		534,208				(2,217,365)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			332,284				324,606
Provision for bad debts			112,794				(1,583)
Gain on sale of assets			(46,594)				(16,613)
Stock based compensation			102,900				145,400
Changes in operating assets and liabilities:
Accounts receivable			1,105,032				1,218,992
Contract assets			(2,639,619)				4,282,495
Other current assets			(172,448)				(323,491)
Accounts payable and accrued expenses			(1,476,931)				1,176,241
Contract liabilities			(3,407,627)				714,879
Net cash provided by (used in) operating activities		($5,556,001)				$5,303,561
Cash flows from investing activities:
Purchases of property and equipment			(976,009)				(485,281)
Sales of property and equipment			46,594				16,687
Investment in associates			0				25,396
Increase in intangible assets			(1,001,481)				0
Net cash used in investing activities		($1,930,896)				($443,198)
Cash flows from financing activities:
Proceeds from exercise of subsidiary options			20,292				64,147
Proceeds from bank loans			0				242,421
Payments on finance lease obligations and loans – net			(119,298)				(115,350)
Net cash provided by (used in) financing activities		($99,006)				$191,218
Effect of exchange rate changes			159,737				281,093
Net increase (decrease) in cash and cash equivalents		($7,426,166)				$5,332,674
Cash and cash equivalents at beginning of the period			27,123,955				17,357,944
Cash and cash equivalents at end of period		$19,697,789				$22,690,618

Schedule 4: Reconciliation of GAAP Net Income (Loss) to Non-GAAP EBITDA
		For the Three Months Ended September 30,
		2026				2025
Net Income (loss) attributable to NetSol		$162,969				($2,357,288)
Non-controlling interest			371,239				139,923
Income taxes			105,126				215,775
Depreciation and amortization			332,284				324,606
Interest expense			111,360				174,611
Interest (income)			(301,068)				(280,974)
EBITDA		$781,910				($1,783,347)
Add back:
Currency exchange (gain) loss			6,811				286,917
Non-cash stock-based compensation			102,900				145,400
Adjusted EBITDA, gross		$891,621				($1,351,030)
Less non-controlling interest (a)			(406,674)				(305,661)
Adjusted EBITDA, net		$484,947				($1,656,691)
(a) The reconciliation of adjusted EBITDA of non-controlling interest to net income attributable to non-controlling interest is as follows:
Net Income (loss) attributable to non-controlling interest		$371,239				$139,923
Income Taxes			25,391				39,805
Depreciation and amortization			72,671				75,085
Interest expense			33,855				48,827
Interest (income)			(93,372)				(79,772)
EBITDA		$409,784				$223,868
Add back:
Currency exchange (gain) loss			(3,110)				81,793
Non-cash stock-based compensation			0				0
Adjusted EBITDA of non-controlling interest		$406,674				$305,661

Companies sign letter of intent to expand operational trials of Apollo humanoid robots; develop framework for commercial deployment through an innovative Robotics-as-a-Service model

GREENWICH, Conn., Nov. 12, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced that it has signed a Letter of Intent (LOI) with AI-powered robotics company Apptronik to expand development of Apptronik technology for deployment at scale through a Robotics-as-a-Service (RaaS) model.

“Humanoid robots are the latest evolution of intelligent automation, and their increasing dexterity will make them one of the most transformative applications of physical AI in logistics,” said GXO CEO Patrick Kelleher. “GXO has deep experience turning advanced automation into operational value at scale. Our expanded work with Apptronik builds on that expertise as we identify and scale the applications where humanoids can deliver the greatest impact for our customers and team members.”

“We started working with GXO in 2024, and through our partnership we’re defining what it takes to put humanoid robots to work in logistics — measured against real operational KPIs in live facilities, and delivering real value. GXO has the network and the operating discipline to take this technology to real scale, across one of the largest logistics footprints in the world,” said Jeff Cardenas, CEO and co-founder of Apptronik. “Our expanded partnership with GXO shows what’s possible when you pair a leading logistics provider with robots designed from the start for thoughtful collaboration with people.”

Under the agreement, GXO and Apptronik will expand joint trials of Apollo in live operations across a range of warehouse workflows, including goods-to-person and person-to-goods picking, case and tote movement, packing and sortation. Beginning in 2027, the trials will validate the safety, security and technical requirements for scaled deployment – with each use case assessed and sequenced against jointly agreed productivity, safety and operational KPIs – and demonstrate how humanoids can work alongside existing automation and GXO team members.

Subject to the success of the deployments and the ability to meet agreed performance, safety and operational KPIs, the companies intend to progress toward global rollout of up to 1,000 Apollo humanoid robots over the next four years, with initial deployment in North America in late 2027. The commercial framework is expected to follow a RaaS structure, allowing GXO to scale humanoid deployment through a flexible, service-based offering.

Building on Shared Progress

GXO and Apptronik’s partnership began in 2024 with a proof-of-concept program to develop practical applications for the Apollo humanoid in a warehouse environment. Earlier this year, Apollo wrapped a successful pilot deployment with GXO in the U.S. focused on autonomous picking for small consumer goods. Additionally, Apptronik and GXO have conducted data collection and live autonomous evaluations on more than 50 different logistics tasks in Apptronik’s Robot Park humanoid robot training facility.    

Apollo is designed to perform repetitive, physically demanding tasks in warehouse environments. The technology is expected to help address labor availability, improve throughput and uptime, and enable employees to focus on higher-value activities.

GXO has a long track record of testing and scaling advanced automation, robotics and AI across its global network. The expanded relationship with Apptronik paves the way for humans and humanoids to work together at scale.

About GXO
GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has over 150,000 team members across more than 1,000 facilities, totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.

About Apptronik
Apptronik is a human-centered physical AI company developing AI-powered robots to support humanity in every facet of life. Our humanoid robot, Apollo, is designed to collaborate thoughtfully with humans—initially in critical industries such as manufacturing and logistics, with future applications in healthcare, the home, and beyond. Apollo is the culmination of more than a decade of development, drawing on Apptronik’s extensive work on 15 previous robots, including NASA’s Valkyrie robot. Apptronik started out of the Human Centered Robotics Lab at the University of Texas at Austin and has nearly 500 employees. Learn more at apptronik.com.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by the company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors the company believes are appropriate in the circumstances.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause or contribute to a material difference include, but are not limited to, the risks discussed in our filings with the SEC and the following: economic conditions generally; supply chain challenges, including labor shortages; competition and pricing pressures; our ability to align our investments in capital assets, including equipment, service centers and warehouses, to our respective customers’ demands; our ability to successfully integrate and realize anticipated benefits, synergies, cost savings and profit improvement opportunities with respect to acquired companies, including the acquisition of Wincanton; acquisitions may be unsuccessful or result in other risks or developments that adversely affect our financial condition and results; our ability to develop and implement suitable information technology systems and prevent failures in or breaches of such systems; our indebtedness; our ability to raise debt and equity capital; litigation; labor matters, including our ability to manage its subcontractors, and risks associated with labor disputes at our customers’ facilities and efforts by labor organizations to organize its employees; risks associated with defined benefit plans for our current and former employees; our ability to attract or retain necessary talent; the increased costs associated with labor; fluctuations in currency exchange rates; fluctuations in fixed and floating interest rates; fluctuations in customer confidence and spending; issues related to our intellectual property rights; governmental regulation, including environmental laws, trade compliance laws, as well as changes in international trade policies and tax regimes; governmental or political actions, including the United Kingdom’s exit from the European Union; natural disasters, terrorist attacks or similar incidents; damage to our reputation; a material disruption of our operations; the inability to achieve the level of revenue growth, cash generation, cost savings, improvement in profitability and margins, fiscal discipline, or strengthening of competitiveness and operations anticipated or targeted; failure in properly handling the inventory of our customers; the impact of potential cyber-attacks and information technology or data security breaches; and the inability to implement technology initiatives or business systems successfully; our ability to achieve Environmental, Social and Governance goals; and a determination by the IRS that the distribution or certain related spin-off transactions should be treated as taxable transactions. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. Such forward-looking statements should therefore be construed in the light of such factors. All forward-looking statements set forth in this release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Forward-looking statements set forth in this release speak only as of the date hereof, and we do not undertake any obligation to update forward-looking statements to reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events, except to the extent required by law.

GXO Media Contacts
Matthew Schmidt 
+1 203-307-2809 
matt.schmidt@gxo.com

Kathleen Juviler
+1 203-921-9121
kathleen.juviler@gxo.com

Apptronik Media Contact
Liz Clinkenbeard
press@apptronik.com 

Attachment

• GXO and Apptronik Expand Partnership to Scale Humanoid Deployment

Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumors

Advancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates for solid tumors through IND-enabling studies; on track to dose first patient in Q4 2027

Paused further enrollment in Phase 3 ALLOHA-2™ study of TSC-101; allowing data to mature and actively seeking strategic partners

Cash and cash equivalents fund operations into the fourth quarter of 2027

WALTHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended September 30, 2026, and provided a corporate update.

“This quarter marked an important step in accelerating TScan’s solid tumor program. We are concentrating all our efforts on our in vivo-engineered TCR-T cell approach for solid tumor indications, where we see an opportunity to bring an exciting new treatment modality to patients in desperate need of better treatment options. Our team is working to advance our two lead candidates through preclinical development and complete the studies required to support clinical entry, with the goal of dosing our first patient by the fourth quarter of next year,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “At the same time, we are actively pursuing strategic partnerships to advance our heme malignancies and autoimmunity programs. We are excited about the progress we have made this year on our in vivo TCR-T candidates and look forward to sharing more of our preclinical data and FDA feedback in early 2027.”

Recent Corporate Highlights

• In September, the Company announced a strategic reorganization to prioritize its in vivo solid tumor program. TScan’s first two therapeutic candidates, one targeting PRAME and the other targeting MAGE-A4, were advanced to IND-enabling studies.
• The Company also provided updated data in September from Cohort C of its Phase 1 ALLOHA™ study of TSC-101 in heme malignancies. At the time of the update, all 14 patients in Cohort C of the study showed complete donor chimerism at their last assessment, including the two patients who had previously relapsed. The Company paused further enrollment in the Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital needed to complete the trial and is actively seeking strategic partnerships. TScan remains committed to tracking the patients enrolled in Cohort C of the Phase 1 study, as well as the 7 patients who were enrolled on the treatment arm of the Phase 3 ALLOHA-2™ study and the five patients enrolled on the control arm of ALLOHA-2.

Pipeline Progress and Upcoming Anticipated Milestones

Solid Tumor Program: The Company’s strategy is to treat patients with in vivo-engineered TCR-T therapy candidates, initially as singleplexed therapy and ultimately as multiplexed therapy. The Company currently has two candidates in IND-enabling studies: one targeting PRAME and the other targeting MAGE-A4.

Anticipated Milestones

• Disclose preclinical data and FDA feedback from pre-IND meetings on TSC-303-A02 (PRAME) and TSC-302-A02 (MAGE-A4) in Q1 2027.
• File the first IND for in vivo-engineered TCR-T for solid tumors in Q3 2027, with first patient dosed in Q4 2027.
• Report initial Phase 1 data on in vivo-engineered TCR-T in H1 2028.

Heme Malignancies Program: TScan’s TCR-T therapy candidate, TSC-101, is designed to treat residual disease and prevent relapse in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). TScan is currently seeking strategic partners for this program.

Anticipated Milestones

• Share updated data on patients treated in Cohort C of the Phase 1 ALLOHA™ study at the upcoming 68^th American Society of Hematology (ASH) Annual Meeting and Exposition in Q4 2026.

Title: Phase 1 (ALLOHA) trial cohort C: TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved outcomes in patients with AML, ALL, or MDS post-allogeneic RIC HCT
Publication Number: 4178
Presentation Date and Time: December 13, 2026, 6:00 – 8:00 pm E.T.

• Share updated data, including >1 year of follow-up time, on Cohort C patients of the ALLOHA™ study, and new data, including >6 months of follow-up time, on patients enrolled in the ALLOHA-2™ study, in the first half of 2027.

Autoimmunity Program: The Company has discovered novel targets for ankylosing spondylitis and other HLA-B*27-associated autoimmune disorders and is currently seeking strategic partners for this program.

Third Quarter 2026 Financial Results

Revenue: Revenue for the third quarter of 2026 was $0.6 million, compared to $2.5 million for the third quarter of 2025. The decrease was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen, which was terminated in August 2026.

R&D Expenses: Research and development (R&D) expenses for the third quarter of 2026 were $25.3 million, compared to $31.7 million for the third quarter of 2025. The decrease of $6.4 million was primarily driven by a decrease in laboratory supplies, research materials, and studies due to the timing in the purchase of supplies and consumables, and decrease spend on contracted services, as well as savings in connection with the 2025 workforce reduction. R&D expenses included non-cash stock compensation expense of $1.0 million and $1.7 million for the third quarter of 2026 and 2025, respectively.

G&A Expenses: General and administrative (G&A) expenses for the third quarter of 2026 were $8.3 million, compared to $7.9 million for the third quarter of 2025. The increase of $0.5 million was primarily due to costs incurred in connection with the 2026 reorganization. G&A expenses included non-cash stock compensation expense of $1.1 million and $1.3 million for the third quarter of 2026 and 2025, respectively.

Net Loss: Net loss was $33.1 million for the third quarter of 2026, compared to $35.7 million for the third quarter of 2025, and included net interest expense of $0.1 million and net interest income of $1.3 million, respectively.

Cash Position: Cash and cash equivalents as of September 30, 2026, were $73.0 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to fund its current operating plan into the fourth quarter of 2027. The Company did not achieve certain non-covenant related milestones by June 30, 2026 as provided under its existing debt agreement. The updated cash runway therefore reflects commencement of the two-year term loan amortization beginning in the fourth quarter of 2026.

Share Count: As of September 30, 2026, the Company had 67,779,255 issued and outstanding shares of common stock, consisting of 63,502,667 shares of voting common stock and 4,276,588 shares of non-voting common stock, as well as 62,246,707 outstanding pre-funded warrants to purchase shares of voting common stock at an exercise price of $0.0001 per share. Pro forma outstanding shares, inclusive of both common stock and pre-funded warrants, were 130,025,962 as of September 30, 2026.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is currently advancing its two lead therapeutic candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells and is advancing a strategy to treat patients with multiplexed TCR-T to overcome the challenge of tumor heterogeneity. In addition, the Company is actively seeking partnerships for its heme and autoimmune programs. To learn more, visit www.tscan.com and connect with us on LinkedIn and X.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan’s plans, progress, and timing relating to TScan’s solid tumor program, including preclinical development, FDA feedback, submission of IND applications, dosing of patients, presentation of data, and strategy regarding singleplexed and multiplexed therapies; TScan’s plans, progress, expectations, and timing relating to the ALLOHA™ and ALLOHA-2™ clinical trials, including presentation of data and the implications of such results and, potential strategic partnerships; TScan’s plans, process, and timing relating TScan’s autoimmunity program; the potential benefits of any of TScan’s proprietary platforms or current or future product candidates in treating patients; TScan’s ability to fund its operating plan into the fourth quarter of 2027 with its existing cash resources; and TScan’s goals and strategy. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan’s TCR-T therapy product candidates; TScan’s expectations regarding its preclinical studies or clinical trials being predictive of future clinical trial results; TScan’s cleared INDs being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the timing of the launch, initiation, progress, expected results and announcements of TScan’s preclinical studies, clinical trials and its research and development programs; TScan’s ability to enroll patients for its clinical trials within its expected timeline; TScan’s plans relating to developing and commercializing its TCR-T therapy product candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy product candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Investor and Media Contact
Caileigh Dougherty
AVP, Head of Corporate Communications & Investor Relations
857-399-9890
cdougherty@tscan.com

TScan Therapeutics, Inc.
Condensed Consolidated Balance Sheet Data
(unaudited, in thousands, except share amounts)
		September 30, 2026				December 31, 2025
Assets
Cash and cash equivalents		$	73,038			$	152,406
Other assets			68,363				76,383
Total assets		$	141,401			$	228,789
Liabilities and Stockholders’ Equity
Total liabilities		$	103,390			$	105,666
Total stockholders’ equity			38,011				123,123
Total liabilities and stockholders’ equity		$	141,401			$	228,789
Common stock and pre-funded warrants outstanding (1)			130,025,962				129,913,390
(1) Includes at September 30, 2026 and December 31, 2025, respectively, 62,246,707 and 73,011,767 issued and outstanding pre-funded warrants to purchase shares of voting common stock at an exercise price of $0.0001 per share.

TScan Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(unaudited, in thousands, except share and per share amounts)
		Three Months Ended September 30,
		2026				2025
Revenue:
Collaboration and license revenue		$	586			$	2,511
Operating expenses:
Research and development			25,291				31,689
General and administrative			8,326				7,874
Total operating expenses			33,617				39,563
Loss from operations			(33,031	)			(37,052	)
Interest and other income, net			721				2,041
Interest expense			(775	)			(699	)
Net loss		$	(33,085	)		$	(35,710	)
Net loss per share, basic and diluted		$	(0.25	)		$	(0.28	)
Weighted average common shares outstanding—basic and diluted (2)			130,025,962				129,835,938
(2) For the three months ended September 30, 2026 and 2025, respectively, 62,246,707 and 73,087,945 shares of the Company’s voting common stock issuable upon exercise of pre-funded warrants are included as outstanding common stock in the calculation of basic and diluted net loss per share.

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced that the Company’s board of directors has declared a cash dividend of $0.34 per share for the quarter ended December 31, 2026. The following are the key dates for the dividends:

Record Date	December 31, 2026
Payment Date	January 15, 2027

About Chicago Atlantic BDC, Inc.

The Company is a specialty finance company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, and has elected to be treated as a regulated investment company for U.S. federal income tax purposes. The Company’s investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a primary focus on cannabis companies. The Company is managed by Chicago Atlantic BDC Advisers, LLC, an investment manager focused on the cannabis industry and other niche or underfollowed sectors. For more information, please visit chicagoatlanticbdc.com.

Forward-Looking Statements

Certain information contained herein may constitute “forward-looking statements” that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors and undue reliance should not be placed thereon. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the Company, its current and prospective portfolio investments, its industry, its beliefs and opinions, and its assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements including, without limitation, the risks, uncertainties and other factors identified in the Company’s filings with the SEC. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date on which the Company makes them. The Company does not undertake any obligation to update or revise any forward-looking statements or any other information contained herein, except as required by applicable law.

Contact:
Lisa Kampf
Tripp Sullivan
SCR Partners, LLC
LIEN@chicagoatlantic.com

– Organizational focus on DURAVYU^TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 –

– DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis –

– Strategic prioritization expected to generate $30 million in annualized savings –

– $118 million in cash, cash equivalents and short-term investments, as of September 30, 2026 –

WATERTOWN, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate developments.

“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “Our conviction in the DME program is further grounded in the positive Phase 2 VERONA trial results, the multi-MOA activity for DURAVYU addressing the distinct biology of DME driven by both inflammatory pathways as well as vascular endothelial growth factor (VEGF), the substantial clinical experience established with DURAVYU, and the opportunity to evaluate the program in two fully enrolled, well-controlled pivotal trials within a year.”

In the Phase 2 VERONA clinical trial in DME, DURAVYU 2.7 mg met the primary endpoint and demonstrated an early and sustained improvement in vision and anatomical control, including a +7.1-letter improvement in best-corrected visual acuity (BCVA) and a 76-micron reduction in central subfield thickness (CST) reduction at Week 24. Seventy-three percent of DURAVYU 2.7 mg patients remained supplement-free through Week 24 versus 50% of aflibercept-treated patients in the control arm. The Phase 3 COMO and CAPRI clinical trials are fully enrolled with over 550 patients and topline data expected early in the fourth quarter of 2027.

R&D Updates:

DURAVYU (vorolanib intravitreal insert) 

Diabetic Macular Edema (DME)

• On July 30, 2026, we announced the pivotal Phase 3 COMO and CAPRI clinical trials completed enrollment, with a total of over 550 patients now enrolled in five months.
  • The identical non-inferiority trials versus an on-label aflibercept control include every six-month re-dosing and follow a clear and recognized regulatory approval pathway.
• Topline data for both DME trials are anticipated early in the fourth quarter of 2027.

Wet Age-Related Macular Degeneration (Wet AMD)

• On August 17, 2026, we announced the Phase 3 LUGANO trial did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept control in the full analysis population, despite demonstrating visual improvement.
  • DURAVYU achieved key secondary endpoints including a 42% reduction in treatment burden achieving superiority versus on-label aflibercept (nominal p-value of <0.0001), with 54% of eyes supplement-free and 79% receiving zero or one supplement up to Week 56, as well as strong anatomic control.
  • DURAVYU maintained a favorable safety profile with repeat dosing in patients. There were no observed occurrences of insert migration, anterior chamber opacities, free-floating drug particles, or retinal vasculitis.
• On October 19, 2026, we announced the Phase 3 LUCIA trial did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2mg aflibercept control in the full analysis population, despite demonstrating visual improvement.
  • DURAVYU achieved key secondary endpoints including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control, consistent with the first Phase 3 LUGANO clinical trial.
  • DURAVYU maintained a favorable safety profile with repeat dosing in patients. There were no observed occurrences of insert migration, anterior chamber opacities, free-floating drug particles, or retinal vasculitis.
• In a pooled analysis of the greater than 50% of patients in both trials who were supplement-free up to Week 56, DURAVYU was observed to be statistically non-inferior in mean change in BCVA versus on-label 2 mg aflibercept control.
• We will conclude the wet AMD program before completion of the full second year of the Phase 3 studies for both LUGANO and LUCIA, while also allowing additional patients to complete year two to support the necessary safety database for a potential new drug application for DME.
• We will complete additional analyses of both the LUGANO and LUCIA data along with the pooled Phase 3 datasets to further assess next steps for DURAVYU as a potential treatment for wet AMD.

Recent and Upcoming Presentations at Medical Conferences

• In July 2026, we delivered multiple oral presentations at the American Society of Retina Specialists (“ASRS”) Annual Meeting supporting DURAVYU’s potentially best-in-class therapeutic profile as a sustained release TKI being developed for multiple indications:
  • A characterization of the multi-mechanism of action of DURAVYU in retinal exudative diseases
  • Overview of key learnings from the Phase 2 DAVIO 2 clinical trial in wet AMD
  • Post-hoc analyses of patients from the Phase 2 DAVIO 2 clinical trial who met Phase 3 criteria
  • Overview of DME clinical program and key learnings: from the Phase 2 VERONA trial to pivotal Phase 3
• In September 2026, we delivered multiple presentations at the Retina Society Annual Meeting, underscoring the potential multi-modal activity of DURAVYU and enthusiasm from the retinal community for new treatment options in serious retinal diseases. This was the first conference where LUGANO data was presented to the retinal community.
  • Bioerodible EYP-1901 (vorolanib intravitreal insert) for Sustained Release of a Tyrosine Kinase Inhibitor for Retinal Exudative Disease
  • LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration: First-Time Vision and Anatomic Outcomes
  • LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration: First-Time Safety and Treatment Burden Outcomes
  • Association Between Central Subfield Thickness Fluctuation and Visual Acuity Outcomes in Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Analysis of the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)
• In October 2026, we delivered multiple podium presentations and symposia at the 26th Euretina Congress, Innovate Retina, and the American Academy of Ophthalmology Annual Meeting (AAO 2026) providing additional detail on the LUGANO dataset, reviewing the mechanism of action and pharmacokinetic characteristics of DURAVYU for sustained release in retinal exudative disease, and reviewing key learnings from the prior Phase 2 studies DAVIO 2 in wet AMD and VERONA in DME.

Recent Corporate Updates

• Following the LUCIA results, our Board of Directors approved a strategic prioritization designed to extend our financial resources and focus on the late-stage DME program. The resulting approximately 53% workforce reduction, as well as associated operational adjustments, are expected to generate an estimated annualized savings of approximately $30 million.

“Capital discipline is now one of our highest priorities,” said George O. Elston, Executive Vice President and Chief Financial Officer. “Our objective is to preserve the resources required to obtain the pivotal DME data, while delivering COMO and CAPRI to the utmost standard. We have multiple levers available to us to further extend our financial runway and we intend to actively evaluate and pursue those opportunities to preserve strategic flexibility and maximize long-term shareholder value.”

Review of Results for the Third Quarter Ended September 30, 2026

For the quarter ended September 30, 2026, total net revenue was $0.8 million compared to $1.0 million for the corresponding period in 2025. Operating expenses for the quarter ended September 30, 2026, totaled $97.6 million versus $63.0 million for the corresponding period in 2025. This increase was primarily attributable to ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME.

Net non-operating income totaled $1.3 million and net loss was $95.6 million, or ($1.07) per share, compared to a net loss of $59.7 million, or ($0.85) per share, for the corresponding period in 2025.

Cash, cash equivalents, and marketable securities as of September 30, 2026, totaled $118 million compared to $306 million as of December 31, 2025.

Financial Outlook

We expect the cash, cash equivalents, and marketable securities as of September 30, 2026, together with the additional $10 million of capital raised subsequent to quarter-end pursuant to our “at-the-market” equity facility and with anticipated operational adjustments, will enable us to fund operations into late third quarter of 2027. We continue to pursue business development, financing and other cost reduction opportunities that could further extend this cash runway.

Conference Call Information

EyePoint will host a conference call today at 8:30 a.m. ET to discuss the results for the third quarter ended September 30, 2026, and recent corporate developments. To access the live conference call, please register at https://edge.media-server.com/mmc/p/4ke9q689. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Forward Looking Statements

EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our cash runway; expectations regarding our strategic prioritization, including our workforce reduction, capital allocation strategy and estimated annual savings; our plans to conclude our Wet AMD program; expectations regarding our clinical development, regulatory and operational plans; our plans to complete additional analyses of the LUCIA and pooled Phase 3 datasets to further assess next steps for DURAVYU as a potential treatment for wet AMD; our expectations regarding DURAVYU’s potential to improve treatment outcomes for patients with wet AMD; our belief that the VERONA findings support DURAVYU’s therapeutic potential in DME; our belief that DURAVYU brings a potential new multi-mechanism of action and treatment paradigm for retinal diseases beyond existing anti-VEGF large molecule ligand blocking therapies; our expectations regarding the timing of the availability and release of DME clinical data, including topline results for Phase 3 COMO and CAPRI clinical trials in DME early in the fourth quarter of 2027; and other statements regarding the Company’s future plans, objectives, strategies and beliefs, as identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” or other words of similar meaning or the use of future dates.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the Company’s clinical development activities; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; uncertainties regarding the Company’s ability to continue as a going concern; the Company may incur additional costs in connection with its strategic prioritization not currently contemplated; the Company’s ability to use business development, financing activities or other operational savings and adjustments to extend its cash runway; the Company’s ability to comply with Nasdaq’s minimum bid compliance requirement; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company’s product candidates; changes in the regulatory environment; disruptions at the FDA; changes in U.S. and international trade policies; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates, including due to unanticipated regulatory compliance issues or warning letters relating to the Company’s manufacturing facilities; the availability of and the need for additional financing; our ability to obtain additional funding to support our clinical development programs; uncertainties regarding the FDA warning letter pertaining to the Company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. A more complete discussion of the risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, in our other filings with the Securities and Exchange Commission (SEC) and in our future reports to be filed with the SEC, which are available at www.sec.gov. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors & Media:

Robin Garner
VP, Corporate Communications & Investor Relations
ir@eyepoint.bio

EYEPOINT, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands)
		September 30,				December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	83,206			$	101,821
Marketable securities			35,007				204,265
Accounts and other receivables, net			259				651
Prepaid expenses and other current assets			6,849				20,105
Inventory			1,665				1,813
Total current assets			126,986				328,655
Operating lease right-of-use assets			19,288				20,223
Other assets			19,863				15,118
Total assets		$	166,137			$	363,996
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses		$	35,757			$	34,884
Other current liabilities			2,750				2,140
Total current liabilities			38,507				37,024
Operating lease liabilities – noncurrent			19,124				20,772
Other noncurrent liabilities			–				87
Total liabilities			57,631				57,883
Stockholders’ equity:
Capital			1,487,584				1,410,130
Accumulated deficit			(1,379,892	)			(1,104,978	)
Accumulated other comprehensive income			814				961
Total stockholders’ equity			108,506				306,113
Total liabilities and stockholders’ equity		$	166,137			$	363,996

EYEPOINT, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data)
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Revenues:
Product sales, net		$	528			$	582			$	995			$	1,297
License and collaboration agreements			49				150				695				16,531
Royalty income			179				234				269				12,923
Total revenues			756				966				1,959				30,751
Operating expenses:
Cost of sales			523				721				1,056				1,691
Research and development			81,670				47,754				237,427				161,825
Sales and marketing			31				26				65				96
General and administrative			15,409				14,490				44,894				40,228
Total operating expenses			97,633				62,991				283,442				203,840
Loss from operations			(96,877	)			(62,025	)			(281,483	)			(173,089	)
Other income (expense):
Interest and other income, net			1,265				2,293				6,519				8,829
Total other income, net			1,265				2,293				6,519				8,829
Net loss before provision for income taxes		$	(95,612	)		$	(59,732	)		$	(274,964	)		$	(164,260	)
Provision for income taxes			—				—				50				(93	)
Net loss		$	(95,612	)		$	(59,732	)		$	(274,914	)		$	(164,353	)
Net loss per common share – basic and diluted		$	(1.07	)		$	(0.85	)		$	(3.15	)		$	(2.35	)
Weighted average common shares outstanding – basic and diluted			89,245				70,168				87,274				69,955

NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November:

Craig-Hallum 17^th Annual Alpha Select Conference

• Format: 1×1 investor meetings
• Date: Tuesday, November 17, 2026
• Location: New York, NY

2026 Jefferies Global Healthcare Conference

• Format: Presentation and 1×1 investor meetings
• Date/Time: Wednesday, November 18, 2026 at 8:00 a.m. GMT (3:00 a.m. ET)
• Location: London, UK

The Jefferies presentation will be webcast live and can be accessed on the Events page of the Company’s website. A replay of the webcast will be available for approximately 90 days following the presentation. Investors interested in meeting with management during either of these conferences should contact their representative at the sponsoring firm to request a meeting.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890